Amgen, Servier Complete Product Pact
Published August 13, 2013
Amgen and Servier have completed their cardiovascular product collaboration agreement from July 8, 2013. Amgen has obtained U.S. commercial rights to Servier's novel oral drug, approved in the EU as Procoralan (ivabradine) for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. S38844 is currently in Phase II development for the treatment of heart failure. Additionally, Servier has obtained an exclusive option to commercialize omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin, which is currently being studied for the treatment of heart failure in patients with systolic dysfunction.
blog comments powered by Disqus